Latest news with #Omada
Yahoo
18-06-2025
- Business
- Yahoo
Omada Health releases new data on its GLP-1 companion program
Omada Health (OMDA) released new data demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss. Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings. Omada analyzed 1,124 members without diabetes who self-reported GLP-1 use to assess the impact of its Enhanced GLP-1 Care Track on medication persistence through 24 weeks. Self-reported medication initiation and persistence were confirmed using objective pharmacy claims data. Previous real-world studies have demonstrated a wide range in medication persistence rates at 12 weeks, 42% to 80%, and 24 weeks, 33% to 74%, after starting GLP-1s. In contrast, members included in this analysis of Omada's Enhanced GLP-1 Care Track demonstrated higher persistence rates-94% through 12 weeks and 84% through 24 weeks Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on OMDA: Disclaimer & DisclosureReport an Issue Omada Health Completes Successful Initial Public Offering
Yahoo
17-06-2025
- Health
- Yahoo
Omada Health's Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks
New GLP-1 analysis reveals that by addressing real-world barriers to persistence, Omada's companion program can help sustain GLP-1 use, delivering on clinical trials' promises SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss.2 Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings.1 Despite a growing body of evidence supporting vast clinical benefits of GLP-1s,3 while results vary widely, one study showed that one-third of people stopped taking their GLP-1 in the first month, and less than half stayed on for more than 12 weeks.4 These data suggest that in the real world, factors like non-persistent medication use mean that many who use GLP-1s for weight management may not see the results reflected in clinical trials. 'While published literature illustrates the incredible potential of GLP-1s, these outcomes are generally limited to those who consistently use their medication long enough to see benefit. In the real world many patients do not receive the necessary support for this to be a reality,' said Sarah Linke, PhD, MPH, Senior Director, Clinical & Translational Research, Omada Health. 'Omada's GLP-1 companion program helps individuals maintain their medication regimen and, in this analysis, helped members achieve clinical trial-level outcomes in real-world settings, which sets the stage for cardiometabolic disease reduction.' Omada analyzed 1,124 members without diabetes who self-reported GLP-1 use to assess the impact of its Enhanced GLP-1 Care Track on medication persistence through 24 weeks. Self-reported medication initiation and persistence were confirmed using objective pharmacy claims data. Previous real-world studies have demonstrated a wide range in medication persistence rates at 12 weeks (42%4 to 80%5) and 24 weeks (33%6 to 74%5) after starting GLP-1s. In contrast, members included in this analysis of Omada's Enhanced GLP-1 Care Track demonstrated higher persistence rates—94% through 12 weeks and 84% through 24 weeks.1 This analysis also found the average weight loss for Omada members that persisted on their medication through 24 weeks was closely aligned with 24-week outcomes from a recent head-to-head clinical trial7 comparing tirzepatide and semaglutide in a similar population. Whereas Omada members who stopped taking their GLP-1 medication any time before 24 weeks lost an average of 7.4% of their body weight, those who remained on their medication through 24 weeks lost an average of 12.1%—a 64% relative increase.1 Providing the right kind of support to enable members to persist with their GLP-1 medication long enough to see benefits can help them achieve clinical trial-level weight loss outcomes, setting the stage for cardiometabolic disease risk reduction. Omada's Enhanced GLP-1 Care Track provides targeted resources for members as they move through their GLP-1 use journey. Members in this companion program receive high-touch care team support to help overcome common barriers to persistence – from education around dose titration, common side effects, and mitigation strategies to nutrition guidance and support from Exercise Specialists to combat muscle loss. Members who plan to stop their medication due to access concerns may receive resources that help them understand their options and navigate the larger healthcare ecosystem. 'We are in the fortunate position that more patients are getting access to these transformative medications,' said Wei-Li Shao, President, Omada Health. 'However, with increased access comes the responsibility to ensure GLP-1 use remains cost-effective by supporting sustainable long-term health benefits. We believe these findings highlight the potential of Omada's program to enhance clinical outcomes with improved medication persistence and a focus on engagement in healthy lifestyle behavior changes." This analysis was conducted through Omada's Insights Lab as part of the ANSWERS (ANalyzing Success of WEight medication with Real-world evidence and Stats) initiative, and builds on more than a decade of insights and 29 peer-reviewed publications assessing the efficacy of behavior change programs to improve chronic disease management. Omada HealthOmada Health is a virtual-first healthcare provider that nurtures lifelong health, one day at a time. Omada care teams implement clinically-validated behavior change protocols for individuals living with diabetes, hypertension, prediabetes, and musculoskeletal issues. With more than a decade of experience and data, and 29 peer-reviewed publications that showcase its clinical and economic results, Omada is designed to help improve health outcomes and contain healthcare costs. Omada's scope exceeds 2,000 customers, including health plans, health systems, and employers ranging in size from small businesses to Fortune 500s. The foundation of Omada's success is a strong, vibrant work culture, which helped earn the company the distinction of becoming an officially certified Great Place to Work®. An industry leader, Omada was the first virtual provider to join the Institute for Healthcare Improvement's Leadership Alliance, reflecting the aim to complement primary care providers for the benefit of members, and affirming its guarantee to every partner: Omada works differently. ContactsRose Ramsethpress@ 1Chang, H., Devaraj, S. M., Naqvi, J. B., & Linke, S. (2025). GLP-1 Medication Persistence, a Key Component of Weight Loss. Omada Health. GLP-1 Medication Persistence, a Key Component of Weight Loss. Omada Health. H., Butsch, W. S., Schulte, R., Casacchia, N. J., Le, P., Boyer, C. B., Griebeler, M. L., Burguera, B., & Rothberg, M. B. (2025). Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obesity, 2025, 1-11. Y., Choi, T., & Al-Aly, Z. (2025). Mapping the effectiveness and risks of GLP-1 receptor agonists. Nature, 31, 951–962. Health Intelligence®. (2024, May). Real‑world trends in GLP‑1 treatment persistence and prescribing for weight management [PDF]. Blue Cross Blue Shield Association. Retrieved June 16, 2025, from 5Hankosky, E. R., Karishma, D., Chinthammit, C., Grabner, M., Stockbower, G., He, X., Mojdami, D., Wenziger, C., & Gibble, T. H. (2025). Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States. Diabetes & Metabolism, 51 (3), 101636. P. P., Urick, B. Y.,Marshall, L. Z., Friedlander, N., Qiu, Y., & Leslie, R. S. (2024). Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. Journal of Managed Care & Specialty Pharmacy, 30 (8), 860-867. 7Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Valderas, E. G., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., & Dunn, J. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity, NEJM, 2025. in to access your portfolio
Forbes
11-06-2025
- Health
- Forbes
InnovationRx: RFK Jr. Purges The Vaccine Advisory Committee
In this week's edition of InnovationRx, we look at RFK Jr.'s vaccine advisory committee purge, a tech billionaire's funding of research on AI and healthcare, Omada's IPO and more. To get it in your inbox, subscribe here. On Monday, Health and Human Services Secretary Robert F. Kennedy Jr. purged the group that advises the CDC on vaccines in order to replace its members with those of his own choosing. The group, known as the Advisory Committee on Immunization Practices, or ACIP, is composed of 17 vaccination experts and is generally not political. In a Wall Street Journal editorial, Kennedy claimed that 'a clean sweep is needed to re-establish public confidence in vaccine science.' The move by RFK Jr., who has long expressed antipathy toward vaccinations and promoted conspiracy theories, was roundly condemned by public health experts. It typically takes a year to vet individual members of the panel, but the new members appear to be scheduled to meet at the next scheduled ACIP meeting in Atlanta later this month. The American Medical Association criticized the ousters in a statement, saying that it 'undermines trust and upends a transparent process that has saved countless lives.' The association noted that it would 'fuel the spread of vaccine-preventable illnesses' at a time when the measles outbreak was ongoing and routine child vaccination rates have been declining. Even before the purge, Kennedy had been chipping away at vaccines. Late last month, he eliminated recommendations for pregnant women and healthy children to receive COVID-19 vaccinations, a move that caused the American Pharmacists' Association to withhold endorsement of the CDC's current COVID vaccination schedule this week. Trump's first Surgeon General, Dr. Jerome Adams, wrote in Time on Tuesday that the changes 'not only jeopardize public health but also threaten to erode trust in our health institutions at a critical time.' Dr. Paul Offit, an infectious disease expert and member of the FDA's independent panel of vaccine advisors, told ABC News that RFK's latest move was extremely dangerous. '[Kennedy] doesn't have a single example to show where a vote by one of these committees has hurt children,' he said. 'In fact, the opposite is true–the votes by this committee over the last 25 years have caused children to suffer less and die less. ACIP should be given awards, not fired.' Samsara cofounder and CEO Sanjit Biswas Samsara Samsara cofounder and CEO Sanjit Biswas built his business by applying AI to an area where that was unusual for its time: industrial and physical operations. Now Biswas, who is worth $4.8 billion by Forbes estimates, wants to apply similar technology to healthcare with his philanthropy. After taking $25 billion (market cap) Samsara public in December 2021, Biswas and his wife Hope Biswas, who has a Ph.D. in epidemiology, established the Biswas Family Foundation with $100 million in funding. The group began making grants in 2023, and has been giving away funds in batches of $15 million a year since. The grants are typically $3 million to $4 million each. 'I have always thought about technology as a way to have a tremendous amount of impact on the world,' Biswas tells Forbes. With the foundation, he hopes to find the sweet spot between startups, which already have access to VC funding, and pure scientific research that's years or even decades away from commercialization—work that, as Biswas puts it, has 'translational impact.' One area that Biswas has funded: using AI to find new uses for existing drugs. One effort he's funded, led by Marinka Zitnik, a biomedical informatics researcher at Harvard Medical School, is building a comprehensive benchmark for computational drug repurposing. While physicians have long prescribed drugs off-label, 'it's not done in a systematic way,' Biswas says. With this project, he hopes researchers will be able to find new uses for existing drugs at scale, including for rare diseases, with the help of tools like deidentified medical records.. Another Biswas-funded project, led by Stanford University's Anshul Kundaje, aims to develop an AI chatbot with access to genomic knowledge to improve diagnosis of cardiovascular disease. And a third effort, led by Katherine Pollard, director of data science and biotechnology at the Gladstone Institutes, is developing personalized diagnosis and treatment for colorectal and skin cancers using machine learning models, which can fit the right treatment to the specific genetic mutation of a patient's tumor. In addition to longstanding researchers like these, Biswas's foundation last December began funding a group of MIT post-doctoral researchers in areas that include AI and health and low-cost diagnostics. These early-career scientists are more likely to stay in the field if they can get funding at that stage, Biswas says—something that's especially critical right now given the drastic cutbacks to NIH and NSF funding under Trump. The Administration's cutbacks have been so large that private efforts—even enormous ones like Bill Gates' recently announced plans to wind down his foundation and give away $200 billion in 20 years—can't possibly fill the gap. While acknowledging the scale of that hole, Biswas (who says that 'in another life I would go do a doctoral dissertation in this area for sure') notes that he plans to increase his philanthropic commitment over time to fund research at the intersection of AI and medicine to better diagnose and treat disease. 'We are leaning in more heavily,' he says. 'The number will go up over time.' On Monday, the FDA approved a new monoclonal antibody from Merck to protect against RSV. The new drug, clesrovimab, will be sold under the brand name Enflonsia. The drug protects infants from RSV shortly before their first season of the disease, which is typically in the fall or winter. In clinical trials, the drug reduced RSV-related hospitalizations by 84%. Sanofi and AstraZeneca already market a similar drug, called Beyfortus, but Enflonsia is simpler because all babies get the same dose in an injection, while the proper dose for Beyfortus depends on the weight of the baby. 'It doesn't matter if the baby's small or if the baby's large–a single shot is sufficient,' Merck's chief medical officer Eliav Barr told Forbes. The next step for Enflonsia is to be evaluated by ACIP later this month, assuming the advisory group still meets as scheduled after its shakeup. Barr said that Merck plans to be ready to bring the drug to market in time for RSV season. Virtual care company Omada Health went public on Friday, following digital health company Hinge Health by a few weeks. The company raised some $150 million from the IPO. That new capital will help Omada (which now has a market cap of $1 billion) expand its business, CEO Sean Duffy said. It currently has more than 700,000 people under active care management for chronic diseases such as diabetes, 31% of whom actually use the company's platform to care for multiple chronic conditions. Omada's shares shot up Friday, closing at $23, a 21% gain over the initial price of $19. But by Tuesday, investors had pushed the stock back down, to $18. The American Academy of Medical Colleges detailed the impact of the Trump Administration's proposed budget cuts on hospital systems in a report released Wednesday. Changes to student loan programs will likely reduce the number of medical students, which will exacerbate the existing doctor shortage at hospitals, according to the report. Proposed changes to how outpatient care is reimbursed could cost hospitals $167 billion over the next 10 years, while proposed cuts to Medicare reimbursement rates will strain already fragile hospital finances. And, of course, NIH budget cuts will eliminate needed research and cancel clinical trials for new medicines. 'Proposed federal actions on multiple fronts not only jeopardize scientific discovery and individual Medicaid patients who might lose health insurance,' the report said. 'They jeopardize the entire academic medicine ecosystem.' Federal lawmakers grilled 23andMe's leaders on the protection of customers' genetic information during the company's bankruptcy sale. Senators from both parties pushed back against the Trump Administration's proposed $18 billion cut to the NIH. 'For God's sake, we lead the world in medical research. Why would we give up on it?' Senator Dick Durbin, Dem.-Ill., said after noting that Northwestern University had not received any NIH funding for 11 weeks. China has adopted a number of policies to incentivize scientists to do their research there. Hundreds of NIH staff signed a letter criticizing proposed cuts to the agency, writing that '[w]e are compelled to speak up when our leadership prioritizes political momentum over human safety and faithful stewardship of public resources.' AI biotech company Recursion laid off 20% of its staff following its pipeline cutback. The company said in an SEC filing that the staff cuts would cost around $11 million in severance and related expenses.
Yahoo
09-06-2025
- Business
- Yahoo
Omada goes public in second recent digital health IPO
This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Omada Health went public Friday, marking the second recent digital health IPO after a dry spell for the sector. The digital chronic condition management company opened at $23 per share, a 21% bump over its public offering price of $19 per share. Omada's debut comes on the heels of virtual musculoskeletal company Hinge Health's IPO last month. 'I think it is definitely a promising bellwether for the industry,' John Beadle, co-founder and managing partner of Aegis Ventures, told Healthcare Dive. Omada, which was founded in 2011 and has raised hundreds of millions of dollars in venture capital funding, offers digital management programs for conditions like diabetes, obesity and hypertension. Care teams also work with patients to build treatment plans and equip users with connected devices like blood pressure cuffs or digital scales. The company filed to go public in May. Now, Omada is trading on Nasdaq under the ticker symbol 'OMDA,' having raised $150 million in its IPO. The firm's public offering price of $19 was at the midpoint of the expected range it released Thursday. Omada's IPO comes as the digital health sector has seen few public offerings in recent years. A surge of companies notched public exits in 2021, but the number has declined significantly in recent years. Many digital health companies that went public during the boom — particularly ones that used mergers with special purpose acquisition companies — performed poorly, and may have been better off as strategic M&A targets, Beadle said. However, the industry seemed poised for more companies to make the leap this year, and their performance could push others to follow in their footsteps, experts told Healthcare Dive late last year. Now, two digital health companies have gone public in recent weeks. Hinge debuted on the New York Stock Exchange in May, opening 23% above its public offering price. Still, the sector isn't seeing a flood of digital health companies moving to go public like in 2021, Beadle said. 'I don't think there's that many companies that are ready and have the operational maturity, growth trajectory [and] outcomes that Hinge and Omada do,' he said. 'But I think both companies were exceptionally well prepared to do well when they went public.' Though Hinge had given back most of its early post-IPO gains by the time of Omada's pricing, its performance still provided a 'good tailwind' for the chronic conditions management firm, Edward Best, co-chair of the capital markets practice at Willkie Farr & Gallagher, said via email. Still, larger macroeconomic conditions will also impact whether more digital health companies decide to make the leap to the public markets. Some technology companies decided to delay their IPOs this spring after tariffs announced by President Donald Trump roiled the markets. Stability is key to the IPO market, as investors will likely choose safer investments during periods of volatility, Best said. Companies need to think about their own operations and readiness to go public as well as broader conditions. 'The IPO market has periods when the window is more open than others. A company that is ready and wants or needs to go public when the window is open should certainly take a long hard look within,' he said. 'Waiting too long could mean missing the window.' Recommended Reading Hinge Health goes public in positive signal for digital health IPOs
Yahoo
09-06-2025
- Business
- Yahoo
Virtual Care Firm Omada Health Leverages GLP-1 Trend For $150 Million NASDAQ Debut
Omada Health, Inc. (NASDAQ:OMDA) closed its first day of trading at $23 per share on Friday, a 21% jump from the IPO price of $19 per share. On Thursday, Omada Health priced its initial public offering of 7.9 million at $19/share. The company filed its initial prospectus in May and updated the document with an expected pricing range of $18 to $20 per share. The company raised $150 million in its IPO. Reuters reported Omada Health's valuation hit $1.28 billion. Omada's revenue increased 57% in the first quarter of 2025 to $55 million from $35.1 million a year earlier, according to its prospectus. For 2024, revenue rose 38% to $169.8 million from $122.8 million the previous company's net loss narrowed to $9.4 million in the first quarter from $19 million a year ago. Omada launched its initial virtual program in diabetes prevention and weight health in 2012. The company delivers virtual care between doctor visits, providing an engaging, personalized, and integrated experience for members designed to improve their health while delivering value for employers, health plans, health systems, pharmacy benefit managers (PBMs), and other entities that cover the cost of programs. According to its S-1 filing, the company had 2,000 customers and more than 679,000 members enrolled in one or more programs as of 31 March. Omada says it has supported more than 1 million members since its launch. The company expanded its virtual care programs to target prediabetes, hypertension, and musculoskeletal conditions. The company estimates that about 20 million people have benefits coverage for one or more Omada programs. According to the company's S-1 filing, this represents about 14% of the self-insured insurance market, 9% of the fully insured market, 1% of the Medicare Advantage market, and 1% of the PBM market. Wall Street Journal, citing President Wei-Li Shao, writes that Omada leadership sees the current moment as the perfect time for an IPO, as GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro have sparked a renewed focus on health problems that can stem from obesity. GLP-1s are expected to be a significant tailwind as more employers are rolling out reimbursement plans for the drugs, CEO Sean Duffy told WSJ. Omada, which signs contracts with employers to offer as a benefit to their workers, aims to be a complementary service that helps patients navigate taking GLP-1s. Omada's IPO is the second digital health IPO in weeks following an extended drought for the industry. In May, digital physical therapy startup Hinge Health Inc. (NYSE:HNGE) debuted on the New York Stock Exchange. Hinge Health priced its IPO of 13.7 million shares at $32 per share. Price Action: OMDA stock is trading lower by 0.43% to $22.90 premarket at last check Monday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Virtual Care Firm Omada Health Leverages GLP-1 Trend For $150 Million NASDAQ Debut originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
